A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 1/2 Terminated
2 enrolled
CONTRAST
Phase 1/2 Terminated
18 enrolled
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Phase 1/2 Terminated
1 enrolled
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
5 enrolled
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Phase 2 Terminated
1 enrolled 8 charts
GASTHER2
Phase 2 Terminated
5 enrolled
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Phase 1/2 Terminated
201 enrolled 71 charts
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase 1/2 Terminated
2 enrolled 9 charts
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Phase 2 Terminated
21 enrolled
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Phase 1 Terminated
6 enrolled
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Phase 2 Terminated
7 enrolled 3 charts
PembroMab
Phase 1/2 Terminated
16 enrolled 6 charts
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
Phase 2 Terminated
4 enrolled 6 charts
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Phase 2 Terminated
84 enrolled 10 charts
HELOISE
Phase 3 Terminated
296 enrolled 16 charts
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
Phase 4 Terminated
4 enrolled 11 charts
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
Phase 2 Terminated
6 enrolled 12 charts
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Phase 1 Terminated
60 enrolled
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
Phase 2 Terminated
26 enrolled